Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Genmab Announces First Phase III Trial Of Daratumumab - Quick Facts

Denmark-based biotechnology company Genmab A/S (GNMSF.PK) said its partner, Janssen Biotech, Inc. would begin a Phase III study of daratumumab in relapsed or refractory multiple myeloma. The trial would compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone.

Genmab's Chief Executive stated: "The daratumumab development program is progressing very well. We are extremely pleased to be able to announce that this study evaluating daratumumab in combination with a core multiple myeloma treatment regime will initiate patient recruitment in the coming months."

The Phase III trial would comprise nearly 500 patients with relapsed or refractory multiple myeloma. Patients would be randomized to receive either daratumumab combined with lenalidomide and dexamethasone, or lenalidomide and dexamethasone alone. The company said the study's primary endpoint is progression free survival.

Click here to receive FREE breaking news email alerts for GENMAB A/S DKK and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving modestly higher in morning trading, stocks showed a substantial move to the downside over the course of the trading day on Wednesday. The major averages pulled back well off their highs for the session, sliding firmly into negative territory. Ebola "czar" Ron Kain is scheduled to meet with President Barack Obama on Wednesday as he begins his efforts to coordinate the government's response to the deadly disease. Klain, who previously served as chief of staff to Vice President Joe Biden and then-Vice President Al Gore, was named as Ebola Response Coordinator last Friday. Potentially complicating the outlook for control of the Senate, the results of a SurveyUSA poll conducted for WXIA-TV in Atlanta suggest that the Georgia Senate race between Republican David Perdue and Democrat Michelle Nunn could be headed for a runoff.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.